Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
An epigenomic ctDNA assay reading methylation signatures predicts recurrence in resected melanoma, potentially guiding adjuvant therapy and follow-up decisions.
Topic
Melanoma
Topic
Melanoma
Hybrid Optimizer Sharpens Deep Learning's Eye for Skin Cancer
A hybrid optimization strategy improves how deep learning models classify skin cancer, Bioengineer.org reports, shifting focus fr…
Florida's Melanoma Burden Concentrated in Older Adults, FAU Reports
Florida Atlantic University finds melanoma cases and deaths in Florida peak among older adults, highlighting late-detection risk…
DNA Methylation Rewrites Melanoma as It Spreads, Study Finds
Melanoma changes its methylation program as it metastasizes, making spread tumors molecularly distinct from the primary lesion —…
Attention-Guided Fair AI Modeling for Skin Cancer Diagnosis Published in Nature
A Nature publication introduces attention-guided fair artificial intelligence modeling for skin cancer diagnosis, aiming to reduc…
MAPK Signaling in Melanoma: From BRAF and NRAS to Combination Therapy
A Frontiers review maps BRAF- and NRAS-driven MAPK signaling in malignant melanoma and lays out the logic behind precision combin…
Skin Cancer Burden Projected to Surge Through 2050
Skin cancer incidence is projected to climb through 2050, with low- and middle-income regions facing the steepest rise, straining…
Vanderbilt Patient With Melanoma Receives TIL Therapy
Vanderbilt Health News has issued a one-line notice confirming a melanoma patient received tumor-infiltrating lymphocyte therapy,…
Melanoma Vaccine 'Breakthrough': Which Cancers Come Next?
Oncology's melanoma vaccine pivot has shifted attention from proof-of-concept to pipeline. The Washington Post's headline framing…
Gut Bacteria Predict Skin Cancer Recurrence, Study Finds
NYU Langone links gut bacteria to skin cancer recurrence, but only when patients share a microbial fingerprint — reframing earlie…